Advanced search
Publication Cover
Infection and Drug Resistance Volume 16, 2023 - Issue
Submit an article Journal homepage
130
Views
4
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Clinical Utility of Contezolid-Containing Regimens in 25 Cases of Linezolid-Intolerable Tuberculosis Patients

Jun Wang1 Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People’s Republic of ChinaView further author information
,
Wenjuan Nie1 Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People’s Republic of ChinaView further author information
,
Liping Ma1 Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-8460-6047View further author information
ORCID Icon,
Qiang Li1 Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People’s Republic of ChinaView further author information
,
Ruixue Geng2 Tuberculosis Department, The Second Hospital of Hohhot, Hohhot, People’s Republic of ChinaView further author information
,
Wenhui Shi1 Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People’s Republic of ChinaView further author information
&
Naihui Chu1 Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information
 show all
Pages 6237-6245 | Received 06 Jul 2023, Accepted 09 Sep 2023, Published online: 19 Sep 2023

References

  • World Health Organization. Global tuberculosis report. Geneva: World Health Organization; 2020. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports. Accessed January 18, 2023.
  • Mirzayev F, Viney K, Linh NN, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J. 2021;57(6):2003300. doi:10.1183/13993003.03300-2020
  • Conradie F, Diacon AH, Ngubane N, et al.; Nix-TB Trial Team. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893–902. doi:10.1056/NEJMoa1901814
  • Du J, Gao J, Yu Y, et al. Low rate of acquired linezolid resistance in multidrug-resistant tuberculosis treated with bedaquiline-linezolid combination. Front Microbiol. 2021;12:655653. doi:10.3389/fmicb.2021.655653
  • Mishra G, Alffenaar J-W, Munje R, Khateeb S. Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: a retrospective multicenter study. Indian J Tuberc. 2023. Available from: https://linkinghub.elsevier.com/retrieve/pii/S001957072300063X.
  • Cattaneo D, Marriott DJ, Gervasoni C. Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerations. Expert Rev Clin Pharmacol. 2023;16(3):219–230. doi:10.1080/17512433.2023.2181160
  • Yang M, Zhan S, Fu L, Wang Y, Zhang P, Deng G. Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Drug Discov Ther. 2022;16(2):99–101. doi:10.5582/ddt.2022.01025
  • Shoen C, DeStefano M, Hafkin B, Cynamon M. In vitro and in vivo activities of contezolid (MRX-I) against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2018;62(8):e00493–e00518. doi:10.1128/AAC.00493-18
  • Nasasira M, Kalyango JN, Mupere E, Baluku JB. Incidence and predictors of adverse drug events among people receiving drug resistant tuberculosis treatment in Uganda: 8-year Retrospective Cohort Study. Ther Clin Risk Manag. 2022;18:1117–1127. doi:10.2147/TCRM.S381800
  • World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Online annexes. Available from: https://apps.who.int/iris/bitstream/handle/10665/332678/9789240007062-eng.pdf. Accessed August 1, 2023.
  • Mishra G. Nix-TB and ZeNix trials: paving the way for shorter regimens for drug-resistant tuberculosis. Asian Pac J Trop Med. 2021;14(10):431–432. doi:10.4103/1995-7645.329004
  • Milosevic TV, Payen VL, Sonveaux P, Muccioli GG, Tulkens PM, Van Bambeke F. Mitochondrial alterations (Inhibition of mitochondrial protein expression, oxidative metabolism, and ultrastructure) induced by linezolid and tedizolid at clinically relevant concentrations in cultured human HL-60 promyelocytes and THP-1 monocytes. Antimicrob Agents Chemother. 2018;62(3):e01599–e01617. doi:10.1128/AAC.01599-17
  • Yuan H, Wu H, Zhang Y, et al. Clinical pharmacology and utility of contezolid in Chinese patients with complicated skin and soft-tissue infections. Antimicrob Agents Chemother. 2022;66(6):e0243021. doi:10.1128/aac.02430-21
  • Wang C, Wang G, Huo F, et al. Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China. Front Med. 2022;9:1067516. doi:10.3389/fmed.2022.1067516
  • Gao JT, Du J, Wu GH, et al. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety. Infect Dis Poverty. 2021;10(1):32. doi:10.1186/s40249-021-00819-2
  • Kang Y, Ge C, Zhang H, Liu S, Guo H, Cui J. Compassionate use of contezolid for the treatment of tuberculous pleurisy in a patient with a leadless pacemaker. Infect Drug Resist. 2022;15:4467–4470. doi:10.2147/IDR.S373082
  • Guo W, Hu M, Xu N, et al. Concentration of contezolid in cerebrospinal fluid and serum in a patient with tuberculous meningoencephalitis: a case report. Int J Antimicrob Agents. 2023;62(2):106875. doi:10.1016/j.ijantimicag.2023.106875
  • Zhang SJ, Yang Y, Sun WW, et al. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China. BMC Infect Dis. 2022;22(1):715. doi:10.1186/s12879-022-07693-9

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.